Incyte Genomics, Inc. (INCY) Reports Q4 EPS Loss of $0.44, Sales Top Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $120.39 +3.07%
Financial Fact:
Diluted (in dollars per share): 0.19
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Diluted (in dollars per share): 0.19
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Incyte Genomics, Inc. (NASDAQ: INCY) reported Q4 EPS of ($0.44), $0.05 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $25.65 million.
For earnings history and earnings-related data on Incyte Genomics, Inc. (INCY) click here.
For earnings history and earnings-related data on Incyte Genomics, Inc. (INCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Incyte (INCY) PT Raised to $117 at RBC Capital
- Incyte (INCY) PT Lowered to $116 at Morgan Stanley
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
